Seeking Alpha

User 11759321

User 11759321
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • A Phase III study shows that a 40mg/1mL dose of Teva's (TEVA) Copaxone given three times a week significantly reduces relapse rates at 12 months in patients with multiple sclerosis, and that the drug is safe and tolerable at this measurement. The current approved dose for Copaxone is 20mg/1mL once a day. (PR) Meanwhile, Teva has signed a five-year deal to commercialize Illumina's (ILMN) Verifi non-invasive pre-natal test in Israel. The test can identify chromosomal abnormalities in fetuses. (PR[View news story]
    Would approval of this drug have any impact on the expiration of TEVA's patent on Copaxone (I.e. - would it be patented separately and, if so, what kind of life would the new patent have?)? Has potential market for the increased dosage been assessed?
    Jul 1 05:57 PM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes